CARsgen Announced 2023 Interim Results

CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

CARsgen’s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

CARsgen’s CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer

CARsgen Announced 2022 Annual Results and Business Updates

CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China

Results of a Collaborative Research on CAR T Technology between CARsgen and Shanghai Cancer Institute Published on Molecular Therapy